Biomarker for Sly Disease (MPS VII) (BioSly)
NCT02298699 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2023-02-13
Summary
Development of a new MS-based biomarker for the early and sensitive diagnosis of Sly disease from blood (plasma)
Conditions
- Developmental Delay
- Skeletal Abnormalities
- Hepatomegaly
- Splenomegaly
Sponsors & Collaborators
-
CENTOGENE GmbH Rostock
lead INDUSTRY
Principal Investigators
-
Peter Bauer, Prof. · Centogene GmbH
Eligibility
- Min Age
- 2 Months
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-08-20
- Primary Completion
- 2021-02-28
- Completion
- 2021-02-28
Countries
- Egypt
- Germany
- India
- Sri Lanka
Study Locations
More Related Trials
-
Krabbe Disease Global Patient Registry
NCT02993796 ·Status: RECRUITING
-
Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease
NCT02416661 ·Status: COMPLETED
-
Mucopolysaccharidosis VII Disease Monitoring Program
NCT03604835 ·Status: RECRUITING
-
Longitudinal Study of Bone Disease in Children with Mucopolysaccharidoses (MPS) I, II, and VI
NCT01521429 ·Status: COMPLETED
-
The Therapeutic Effect of Thalidomide in Syringomyelia
NCT06268093 ·Status: RECRUITING ·Phase: PHASE2
-
ABI-009 (Nab-sirolimus) in Patients With Genetically-confirmed Leigh or Leigh-like Syndrome
NCT03747328 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study to Detect Unrecognized Mucopolysaccharidosis in Children Visiting Rheumatology, Hand or Skeletal Dysplasia Clinics
NCT01675674 ·Status: TERMINATED
-
A Natural History Study of Biomarkers and Clinical Outcomes in Mucopolysaccharidosis Type IIIA (MPS IIIA; Sanfilippo Syndrome)
NCT05523206 ·Status: COMPLETED
-
Observational Study of Patients With Mucopolysaccharidosis (MPS) VI Who Previously Participated in ASB-00-02
NCT01387854 ·Status: COMPLETED
-
A Study of Mucopolysaccharidosis Type IIIB (MPS IIIB)
NCT02493998 ·Status: COMPLETED
-
An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1
NCT03259633 ·Status: APPROVED_FOR_MARKETING
-
Biomarkers and Cardiac Imaging Diagnostic Assay for Monitoring Patients With Fabry Disease
NCT05698901 ·Status: RECRUITING
-
Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine
NCT00975689 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SEL-302 in Pediatric Subjects With MMA
NCT05778877 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Natural History Study to Characterise the Course of Disease Progression in Participants With Mucopolysaccharidosis Type IIIB
NCT02293408 ·Status: TERMINATED
-
Study of AAVrh10-h.SGSH Gene Therapy in Patients With Mucopolysaccharidosis Type IIIA (MPS IIIA)
NCT03612869 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Fabry Disease in Cerebrovascular Disease
NCT02859363 ·Status: UNKNOWN
-
Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies
NCT00975819 ·Status: COMPLETED ·Phase: PHASE2
-
Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM
NCT00490789 ·Status: UNKNOWN ·Phase: PHASE2
-
A Retrospective Chart Review of Deceased Patients With Mucopolysaccharidosis Type IIIB
NCT02293382 ·Status: COMPLETED
-
Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder
NCT06261060 ·Status: RECRUITING ·Phase: PHASE2
-
Safety and Tolerability of VGR-R01 for Patients With Bietti Crystalline Dystrophy
NCT05694598 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI
NCT00048620 ·Status: COMPLETED ·Phase: PHASE1
-
Natural History of the Progression of X-Linked Retinitis Pigmentosa
NCT04926129 ·Status: COMPLETED
-
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
NCT06789913 ·Status: RECRUITING ·Phase: PHASE2